- Home
- TNXP vs ABSI Comparison
TNXP vs ABSI Comparison
Compare TNXP & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- ABSI
- Stock Information
- Founded
- TNXP 2007
- ABSI 2011
- Country
- TNXP United States
- ABSI United States
- Employees
- TNXP N/A
- ABSI N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- ABSI Health Care
- Exchange
- TNXP Nasdaq
- ABSI Nasdaq
- Market Cap
- TNXP 335.6M
- ABSI 338.0M
- IPO Year
- TNXP N/A
- ABSI 2021
- Fundamental
- Price
- TNXP $51.35
- ABSI $2.93
- Analyst Decision
- TNXP Buy
- ABSI Strong Buy
- Analyst Count
- TNXP 1
- ABSI 5
- Target Price
- TNXP $70.00
- ABSI $8.08
- AVG Volume (30 Days)
- TNXP 1.8M
- ABSI 6.8M
- Earning Date
- TNXP 08-11-2025
- ABSI 08-12-2025
- Dividend Yield
- TNXP N/A
- ABSI N/A
- EPS Growth
- TNXP N/A
- ABSI N/A
- EPS
- TNXP N/A
- ABSI N/A
- Revenue
- TNXP $9,831,000.00
- ABSI $4,138,000.00
- Revenue This Year
- TNXP $22.87
- ABSI $74.53
- Revenue Next Year
- TNXP $711.66
- ABSI $296.01
- P/E Ratio
- TNXP N/A
- ABSI N/A
- Revenue Growth
- TNXP N/A
- ABSI 27.32
- 52 Week Low
- TNXP $6.76
- ABSI $2.01
- 52 Week High
- TNXP $130.00
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- TNXP 55.76
- ABSI 49.27
- Support Level
- TNXP $42.12
- ABSI $2.80
- Resistance Level
- TNXP $69.97
- ABSI $3.40
- Average True Range (ATR)
- TNXP 6.06
- ABSI 0.21
- MACD
- TNXP 1.01
- ABSI -0.01
- Stochastic Oscillator
- TNXP 45.73
- ABSI 28.79
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.